Posted in | News | Gold

Stellar Pacific Ventures Reports Primary Assay Results from Solotomo Discovery

Stellar Pacific Ventures has announced the initial assay results from the 2011 drilling campaign conducted at Zones B3 and B1 during November 2011.

The company has obtained and collected the assay results of six holes out of 27 holes, which were drilled at the Zone B3. It has encountered 2.03 g/t gold over 28 m in the hole B3-11-04 and 14.29 g/t gold over 6 m in the hole B3-11-05. These two holes have validated the significant and high-grade width prospect of the B3 gold formation outlined through drilling over a strike of 1,050 m.

Stellar’s CEO and President, Maurice Giroux, has stated that the gold mineralization in the Zone B3 is consistent over 1,050 m of the strike length and has demonstrated high-grade elements united to extensive thickness of up to 35 m in the hole B3-26. The zone B3 is exposed in every direction and has one limb out of the three diverse gold formations found and called as SOLOTOMO discovery.

The three structures drilled are called the Solotomo Pit, B1 and B3 and accumulate oxide gold mineralization for over 1,800 linear metres. A core drill program has been planned on the three structures. In line with the indication of the oxide zone, core drilling must direct a significant resource estimate on the three zones.

The company conducted 3,000 m of infill drilling at B1 and B3 zone. It drilled 15 holes at zone B1 and 27 holes at zone B3.

It has performed 1,400 linear metres, totaling 11 trenches. These trenches were explored across B1 and B3 zones to 4 m depth and across the Solotomo pit zone’s south expansion.

The field part of an aerial radiometric and magnetic survey was conducted by Xcalibur Airborne Geophysics of South Africa over the Balandougou Concession. The survey has included around 5,691 line-km of flight lines at spacing of 100 m, oriented towards the north-south direction.

Joel Scanlon

Written by

Joel Scanlon

Joel relocated to Australia in 1995 from the United Kingdom and spent five years working in the mining industry as an exploration geotechnician. His role involved utilizing GIS mapping and CAD software. Upon transitioning to the North Coast of NSW, Australia, Joel embarked on a career as a graphic designer at a well-known consultancy firm. Subsequently, he established a successful web services business catering to companies across the eastern seaboard of Australia. It was during this time that he conceived and launched News-Medical.Net. Joel has been an integral part of AZoNetwork since its inception in 2000. Joel possesses a keen interest in exploring the boundaries of technology, comprehending its potential impact on society, and actively engaging with AI-driven solutions and advancements.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Scanlon, Joel. (2019, February 18). Stellar Pacific Ventures Reports Primary Assay Results from Solotomo Discovery. AZoMining. Retrieved on November 21, 2024 from https://www.azomining.com/News.aspx?newsID=5593.

  • MLA

    Scanlon, Joel. "Stellar Pacific Ventures Reports Primary Assay Results from Solotomo Discovery". AZoMining. 21 November 2024. <https://www.azomining.com/News.aspx?newsID=5593>.

  • Chicago

    Scanlon, Joel. "Stellar Pacific Ventures Reports Primary Assay Results from Solotomo Discovery". AZoMining. https://www.azomining.com/News.aspx?newsID=5593. (accessed November 21, 2024).

  • Harvard

    Scanlon, Joel. 2019. Stellar Pacific Ventures Reports Primary Assay Results from Solotomo Discovery. AZoMining, viewed 21 November 2024, https://www.azomining.com/News.aspx?newsID=5593.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.